Pharma’s push into direct-to-patient sales is reshaping the front end of drug distribution, but wholesalers like Cencora, McKesson, and Cardinal Health remain indispensable as the backbone of the ...
Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...
TipRanks on MSN
AstraZeneca Reports Strong Growth and Pipeline Success
AstraZeneca ( ($AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca is ...
Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.
The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.
Investor's Business Daily on MSN
AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar
AstraZeneca stock jumped Thursday after the drugmaker reported better-than-expected third-quarter sales and earnings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback